Impact of the immune reconstitution inflammatory syndrome (IRIS) on mortality and morbidity in HIV-infected patients in Mexico.

PubWeight™: 1.02‹?› | Rank: Top 15%

🔗 View Article (PMC 3732828)

Published in Int J Infect Dis on April 13, 2011

Authors

Irma Hoyo-Ulloa1, Pablo F Belaunzarán-Zamudio, Brenda Crabtree-Ramirez, Arturo Galindo-Fraga, María Eugenia Pérez-Aguinaga, Juan G Sierra-Madero

Author Affiliations

1: Departamento de Infectología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Tlalpan, Mexico City, Mexico.

Articles citing this

Immune reconstitution inflammatory syndrome: incidence and implications for mortality. AIDS (2012) 1.88

Immune reconstitution inflammatory syndrome in HIV-infected patients. HIV AIDS (Auckl) (2015) 1.61

Immune reconstitution inflammatory syndrome: the trouble with immunity when you had none. Nat Rev Microbiol (2012) 1.45

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of a Chemokine Receptor 5 (CCR5) Antagonist to Decrease the Occurrence of Immune Reconstitution Inflammatory Syndrome in HIV-Infection: The CADIRIS Study. Lancet HIV (2014) 0.85

Vitamin D, d-dimer, Interferon γ, and sCD14 Levels are Independently Associated with Immune Reconstitution Inflammatory Syndrome: A Prospective, International Study. EBioMedicine (2016) 0.85

New insights into immune reconstitution inflammatory syndrome of the central nervous system. Curr Opin HIV AIDS (2014) 0.82

Incidence of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome and impact on patient outcome. PLoS One (2013) 0.77

Extensive Central Nervous System Cryptococcal Disease Presenting as Immune Reconstitution Syndrome in a Patient with Advanced HIV: Report of a Case and Review of Management Dilemmas and Strategies. Infect Dis Rep (2014) 0.76

Hospital days attributable to immune reconstitution inflammatory syndrome in persons living with HIV before and after the 2012 DHHS HIV guidelines. AIDS Res Ther (2017) 0.75

Hospital days attributable to immune reconstitution inflammatory syndrome in persons living with HIV before and after the 2012 DHHS HIV guidelines. AIDS Res Ther (2017) 0.75

Low incidence of the immune reconstitution inflammatory syndrome among HIV-infected patients starting antiretroviral therapy in Gabon: a prospective cohort study. Infection (2017) 0.75

Successful repeat ECMO in a patient with AIDS and ARDS. BMJ Case Rep (2017) 0.75

Articles cited by this

Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet (2006) 31.79

Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA (2006) 17.93

Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med (2005) 8.13

Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis (2008) 5.94

Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS (2006) 5.87

Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS (2005) 5.51

Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS (2005) 5.08

Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis (2010) 4.56

Immune restoration disease after antiretroviral therapy. AIDS (2004) 4.54

Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS (2008) 4.36

Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme. Int J Epidemiol (2007) 3.22

Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS (2005) 3.16

Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. Clin Infect Dis (2009) 2.82

Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis (2006) 2.72

CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa. BMC Infect Dis (2006) 2.68

Excessive early mortality in the first year of treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited settings. AIDS Res Hum Retroviruses (2008) 2.61

Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis (2006) 2.52

Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med (2000) 2.37

Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J Infect (2006) 2.25

The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy. HIV Med (2005) 1.95

Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia. AIDS (2007) 1.88

Herpes zoster as an immune reconstitution disease after initiation of combination antiretroviral therapy in patients with human immunodeficiency virus type-1 infection. Am J Med (2001) 1.85

Immune reconstitution inflammatory syndrome: risk factors and treatment implications. J Acquir Immune Defic Syndr (2007) 1.82

Defining immune reconstitution inflammatory syndrome: evaluation of expert opinion versus 2 case definitions in a South African cohort. Clin Infect Dis (2009) 1.52

Low mortality in HIV-infected patients starting highly active antiretroviral therapy: a comparison with the general population. AIDS (2004) 1.24

Immune restoration and CD4+ T-cell function with antiretroviral therapies. AIDS (2001) 1.21

Brief report: effectiveness of combination antiretroviral therapy on survival and opportunistic infections in a developing world setting: an observational cohort study. J Acquir Immune Defic Syndr (2007) 1.19

Tuberculosis manifested by immune reconstitution inflammatory syndrome during HAART. AIDS (2007) 1.16

Assessing the contribution of the immune reconstitution inflammatory syndrome to mortality in developing country antiretroviral therapy programs. Clin Infect Dis (2009) 0.95

Articles by these authors

Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr (2014) 2.79

Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis (2015) 1.61

Improving outcome of human immunodeficiency virus-infected patients in a Mexican intensive care unit. Arch Med Res (2007) 0.97

Early loss of measles antibodies after MMR vaccine among HIV-infected adults receiving HAART. Vaccine (2009) 0.93

Molecular analysis of Mycobacterium tuberculosis strains with an intact pks15/1 gene in a rural community of Mexico. Arch Med Res (2008) 0.88

Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae A case-control study. Int J Infect Dis (2008) 0.87

Effectiveness of highly active antiretroviral therapy (HAART) among HIV-infected patients in Mexico. AIDS Res Hum Retroviruses (2010) 0.86

[Factors associated with Clostridium difficile disease in a tertiary-care medical institution in Mexico: a case-control study]. Rev Invest Clin (2010) 0.80

Vancomycin-resistant enterococci, Mexico City. Emerg Infect Dis (2007) 0.78

[Active tuberculosis in a cohort of HIV-infected inmates in a prison in Mexico City: clinical and epidemiological characteristics]. Salud Publica Mex (2013) 0.76

Epidemiology and clinical characteristics of Staphylococcus aureus bloodstream infections in a tertiary-care center in Mexico City: 2003-2007. Rev Invest Clin (2011) 0.76

The maraviroc expanded access program - safety and efficacy data from an open-label study. HIV Clin Trials (2015) 0.75

Long-term renal graft function and survival in patients with high-risk for cytomegalovirus infection receiving preemptive therapy. Rev Invest Clin (2009) 0.75

Rapid detection of ESBL-producing gram-negative bacteria isolated from blood: a reasonable and reliable tool for middle and low resource countries. Rev Invest Clin (2009) 0.75

Concordance between two enzyme immunoassays for the detection of Clostridium difficile toxins. Arch Med Res (2010) 0.75

[Epidemic influenza in Mexico: the broken dogma and its lessons]. Rev Invest Clin (2009) 0.75

[Challenges in controlling the spread of ebola and the need for a preparedness plan in México]. Rev Invest Clin (2015) 0.75

[Infections in solid organ transplant recipients]. Rev Invest Clin (2006) 0.75

Post-emergency: providing effective, sustainable, life-long care to everyone with AIDS. Indian J Med Res (2006) 0.75